Truist lowered the firm’s price target on Teladoc (TDOC) to $9 from $10 and keeps a Hold rating on the shares. The firm is updating its model after the company’s Q1 results with expectations of slightly lower 2026 EBITDA, the analyst tells investors in a research note. Longer term, Truist notes that with about 90M U.S. members having access to its offerings, Teladoc has the scale and depth to take advantage of various growth opportunities across the healthcare continuum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc Approves Key Proposals at Annual Meeting
- Hinge Health Stock (HNGE) Gains 17% in Market Debut on NYSE
- Hinge Health (HNGE) Prices IPO at $32 a Share Amid Strong Demand from Investors
- Teladoc call volume above normal and directionally bullish
- Hold Rating for Teladoc Amid UpLift Acquisition and Adjusted EBITDA Guidance Revision